## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.8% below STRENGTH zone (3.0-6.0%); PEG 1.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($112.27)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 0, Bearish: 2)

**1. UBS reiterates Buy rating on DaVita stock, maintains $186 price target**
- Source: Investing.com | 20251215T160807 | Somewhat-Bullish | Relevance: 100%
- UBS has reaffirmed its Buy rating on DaVita (NYSE:DVA) stock, setting a price target of $186.00, which suggests a 53% upside from its current trading price. The firm cites DaVita's solid financial health and long-term operating income growth expectations of 3-7%, despite a recent earnings per share miss in Q3 2025. DaVita's growth framework includes contributions from U.S. dialysis, Integrated Kidney Care, and international business, with IKC projected to reach breakeven by 2026.

**2. DaVita Inc. Stock Underperforms Monday When Compared To Competitors**
- Source: 富途牛牛 | 20251215T220820 | Somewhat-Bearish | Relevance: 100%
- DaVita Inc. (DVA) stock underperformed on Monday compared to its competitors. The article briefly mentions Unity Software (U.US) reporting strong Q4 revenue of $609 million, exceeding estimates, but also a quarterly loss of 66 cents per share.

**3. UBS reiterates Buy rating on DaVita stock, maintains $186 price target**
- Source: Investing.com Nigeria | 20251215T170754 | Neutral | Relevance: 100%
- UBS has reiterated its Buy rating on DaVita (NYSE:DVA) stock, setting a price target of $186.00, which suggests a potential 53% upside. The investment firm projects DaVita's long-term adjusted operating income growth to be in the 3-7% range, driven by contributions from U.S. dialysis operations, Integrated Kidney Care (IKC), and international business. This outlook comes despite a recent Q3 2025 earnings miss, with the company aiming for IKC segment breakeven by 2026.

**4. UBS reiterates Buy rating on DaVita stock, maintains $186 price target**
- Source: Investing.com UK | 20251215T152010 | Somewhat-Bullish | Relevance: 100%
- UBS has re-affirmed its Buy rating for DaVita (NYSE:DVA) stock, setting a price target of $186.00, which suggests a 53% upside from its current trading price. The firm cites DaVita’s solid financial health and long-term adjusted operating income growth expectations of 3-7%, despite a recent Q3 2025 earnings per share and revenue miss. UBS also noted consistent growth frameworks and anticipated breakeven for DaVita's Integrated Kidney Care segment in 2026.

**5. Is DaVita Stock Underperforming the Dow?**
- Source: Markets Financial Content | 20251215T140500 | Bearish | Relevance: 100%
- DaVita Inc. (DVA), a mid-cap company providing kidney dialysis services, has experienced a significant underperformance compared to the Dow Jones Industrials Average ($DOWI). Its stock has decreased by 32.4% from its 52-week high, dropped 8.9% in the last three months, and declined 21.2% over the past year, while the DOWI has seen gains. Analysts are cautious, rating DVA as a "Hold" with a modest price target premium, particularly after a disappointing Q3 2025 due to higher costs, lower volumes, and a ransomware attack.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 4 ($55.95M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $56M sold (4 transactions in 90 days).
2. High short interest (21.2%, 6.2 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 13.1% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +1.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.16 suggests fair value with growth premium. Forward P/E 9.3x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($56.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.4B |
| Beta | 0.99 |
| 52W Range | $113.97 - $179.60 |
| Short Interest | 21.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.16 |
| Forward P/E | 9.3 |
| Current P/E | 11.0 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.6% to 0.8% (+1.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.1pp (needs >3.0% for momentum thesis). MRS_5 (-0.6%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.87x), long-term trend not supportive. RSI neutral at 44. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.85% (CS: 46) | Neutral |
| RSI_14 | 43.9 | Neutral |
| MACD Histogram | 0.40 | Bullish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 0.965x | Below |
| vs SMA200 | 0.869x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $117.91
- **Stop Loss:** $112.27 (4.8% risk)
- **Target:** $123.55 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 177
- **Position Value:** $20,870.07
- **Portfolio %:** 20.87%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*